AL
ALVOW
Alvotech
$0.3301
0.00%
$92.5M
No data for this timeframe.
Vol
Market Cap$92.5M
Cap SizeMicro Cap
SEC Reports4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. N4·CIK 0001898416·Prev Close $0.3301
Recent Activity
Jun 8, 2026
SEC
Alvotech filed its Q1 2026 6-K, reporting total revenues of $105.9M (down 20% YoY from $132.8M) and a profit of $1.0M (d
6-K — Impact 6/10
Jun 4, 2026
SEC
Alvotech resubmitted U.S. Biologics License Applications for AVT05 (biosimilar to Simponi/Simponi Aria) and AVT06 (biosi
6-K — Impact 6/10
May 11, 2026
SEC
Alvotech disclosed that the FDA completed a routine cGMP surveillance inspection at its Reykjavik facility, concluding w
6-K — Impact 4/10
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 4.5/10.
MIXED
6-K
6/10
Alvotech filed its Q1 2026 6-K, reporting total revenues of $105.9M (down 20% YoY from $132.8M) and
Jun 8, 2026
BULLISH
6-K
6/10
Alvotech resubmitted U.S. Biologics License Applications for AVT05 (biosimilar to Simponi/Simponi Ar
Jun 4, 2026
NEUTRAL
6-K
4/10
Alvotech disclosed that the FDA completed a routine cGMP surveillance inspection at its Reykjavik fa
May 11, 2026
NEUTRAL
6-K
2/10
Alvotech filed a 6-K announcing that General Counsel Tanya Zharov is stepping down after six years,
May 4, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | -18.6% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.2B | 52.0% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.7B | 12.2% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.8B | 18.6% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.